Loading...
BXRX.Q logo

Baudax Bio, Inc.OTCPK:BXRX.Q Stock Report

Market Cap US$52.0
Share Price
US$0.000001
My Fair Value
n/a
1Yn/a
7D0%
Portfolio Value
​
View

Baudax Bio, Inc.

OTCPK:BXRX.Q Stock Report

Market Cap: US$52.0

Baudax Bio (BXRX.Q) Stock Overview

A biotechnology company, develops and commercializes products for hospital and other acute care related settings. More details

BXRX.Q fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($52)

Latest financial reports are more than a year old

Shares are highly illiquid


BXRX.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Baudax Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Baudax Bio
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.0001
52 Week LowUS$0.000001
Beta0
1 Month Change-99.00%
3 Month Change0%
1 Year Changen/a
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Aug 30

Baudax Bio stock down after pricing $6.2M equity offering

Baudax Bio (NASDAQ:BXRX) stock plunges 34% in a premarket session after pricing public offering of 11,819,172 shares of its common stock together with accompanying common stock purchase warrants, at $0.525 per share, for gross proceeds of ~$6.2M. Each share of common stock (or pre-funded warrant) was sold in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $0.525 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $0.525 per share. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. Offering is expected to close on or about September 1, 2022. Net proceeds will be used for pipeline development activities and general corporate purposes.
Seeking Alpha • Aug 22

Baudax Bio to get US patent linked to pain drug Anjeso

Baudax Bio (NASDAQ:BXRX) said the U.S. Patent and Trademark Office (USPTO) provided a notice of allowance for a patent application covering the use of multiple doses of pain drug Anjeso. The patent application No. 16/297,095, titled 'Methods of administering intravenous meloxicam in a bolus dose,' includes claims covering the use of multiple doses of Anjeso to treat moderate to severe pain resulting in a reduction in summed pain intensity difference and also a reduction in the use of rescue analgesia 48 hours following the first dose, the company noted in an Aug. 22 press release. The patent would expiry in March 2039, unless extended. "The ‘095 Application is expected to provide a significant barrier for generic entry and are expected to be joined by other patents currently pending in the USPTO," said Baudax President and CEO Gerri Henwood.
Seeking Alpha • Aug 11

Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M

Baudax Bio press release (NASDAQ:BXRX): Q2 GAAP EPS of -$1.05 beats by $0.22. Revenue of $0.3M (+50.0% Y/Y). As of June 30, 2022, Baudax Bio had cash and cash equivalents of $5.2 million. Shares +2.62% PM
Seeking Alpha • Jul 06

Cosette Pharmaceuticals appoints Rick Casten as CFO

Cosette Pharmaceuticals has announced the appointment of Rick Casten as CFO, bolstering its executive leadership team. Prior to joining Cosette, he served as CFO of Baudax Bio (NASDAQ:BXRX). Before Baudax, Rick served as Vice President - Finance, Controller and Treasurer of Lupin Pharmaceuticals.
Seeking Alpha • Sep 09

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

Baudax Bio has been a miserable investment so far as the share price remains under $1.00 per share and the market cap continues to deteriorate. The company recently reported abysmal Q2 earnings with a big miss on EPS and revenue. However, the company did reveal some encouraging commercial trends that are not evident in financials. I point out a few bullish highlights that could lead to a turnaround once the pandemic is under control. However, investors need to accept the possibility these COVID-19 headwinds are likely to endure. I reveal my plan for managing my upsized BXRX position and how I intend to generate some profit along the way.
Analysis Article • Feb 17

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

Shareholder Returns

BXRX.QUS PharmaceuticalsUS Market
7D0%-1.5%2.6%
1Yn/a30.4%26.2%

Return vs Industry: Insufficient data to determine how BXRX.Q performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BXRX.Q performed against the US Market.

Price Volatility

Is BXRX.Q's price volatile compared to industry and market?
BXRX.Q volatility
BXRX.Q Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: BXRX.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BXRX.Q's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/aGerri Henwoodwww.baudaxbio.com

Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.

Baudax Bio, Inc. Fundamentals Summary

How do Baudax Bio's earnings and revenue compare to its market cap?
BXRX.Q fundamental statistics
Market capUS$52.00
Earnings (TTM)-US$59.20m
Revenue (TTM)US$1.27m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is BXRX.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BXRX.Q income statement (TTM)
RevenueUS$1.27m
Cost of RevenueUS$7.01m
Gross Profit-US$5.74m
Other ExpensesUS$53.46m
Earnings-US$59.20m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did BXRX.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/12 17:13
End of Day Share Price 2026/04/17 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Baudax Bio, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBrean Capital Historical (Janney Montgomery)
Jason ButlerCitizens JMP Securities, LLC
Gregory AurandNOBLE Capital Markets, Inc.